CN107468898A - 一种糖尿病患者专用食品及其制作方法 - Google Patents
一种糖尿病患者专用食品及其制作方法 Download PDFInfo
- Publication number
- CN107468898A CN107468898A CN201710812310.7A CN201710812310A CN107468898A CN 107468898 A CN107468898 A CN 107468898A CN 201710812310 A CN201710812310 A CN 201710812310A CN 107468898 A CN107468898 A CN 107468898A
- Authority
- CN
- China
- Prior art keywords
- extract
- food
- diabetic
- powder
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 71
- 235000013305 food Nutrition 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000000843 powder Substances 0.000 claims abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 51
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000011669 selenium Substances 0.000 claims abstract description 31
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 25
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 23
- 229960003080 taurine Drugs 0.000 claims abstract description 21
- 244000302512 Momordica charantia Species 0.000 claims abstract description 20
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 20
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 20
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 20
- 240000000249 Morus alba Species 0.000 claims abstract description 19
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 19
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 18
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 18
- 241000414067 Inonotus obliquus Species 0.000 claims abstract description 18
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims abstract description 17
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 17
- 229940064064 purslane extract Drugs 0.000 claims abstract description 16
- 244000269722 Thea sinensis Species 0.000 claims abstract description 15
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 15
- 239000011720 vitamin B Substances 0.000 claims abstract description 15
- 235000009569 green tea Nutrition 0.000 claims abstract description 14
- 229940046001 vitamin b complex Drugs 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 235000019441 ethanol Nutrition 0.000 claims description 25
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 24
- 229940091258 selenium supplement Drugs 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- 241000522254 Cassia Species 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- -1 is spaced 1 day Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- 241000756042 Polygonatum Species 0.000 claims description 7
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 235000013616 tea Nutrition 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 3
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 3
- 241000723347 Cinnamomum Species 0.000 claims description 3
- 244000228367 Lewisia rediviva Species 0.000 claims description 3
- 235000007279 Lewisia rediviva Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 3
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000017803 cinnamon Nutrition 0.000 claims description 3
- 230000006196 deacetylation Effects 0.000 claims description 3
- 238000003381 deacetylation reaction Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000028161 membrane depolarization Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 150000003648 triterpenes Chemical class 0.000 claims description 3
- 244000234609 Portulaca oleracea Species 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 53
- 230000000694 effects Effects 0.000 abstract description 32
- 229940125396 insulin Drugs 0.000 abstract description 28
- 102000004877 Insulin Human genes 0.000 abstract description 26
- 108090001061 Insulin Proteins 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 24
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 9
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 235000006708 antioxidants Nutrition 0.000 abstract description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 5
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 3
- 206010012655 Diabetic complications Diseases 0.000 abstract description 3
- 210000004413 cardiac myocyte Anatomy 0.000 abstract description 3
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 230000006870 function Effects 0.000 description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 9
- 210000000496 pancreas Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000019158 vitamin B6 Nutrition 0.000 description 7
- 239000011726 vitamin B6 Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 208000002177 Cataract Diseases 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 241000219304 Portulacaceae Species 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 206010018473 Glycosuria Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229930185803 charantin Natural products 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- FBZONXHGGPHHIY-UHFFFAOYSA-N xanthurenic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC(O)=C21 FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000747105 Fuscoporia Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101710090680 Hemoglobinase Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000009815 Momordica Nutrition 0.000 description 1
- 241000218984 Momordica Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000007726 cellular glucose metabolism Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明是一种糖尿病患者专用食品,有富硒菇粉;肉桂提取物;玉竹提取物;苦瓜粉;桑叶粉;马齿苋提取物;桦褐孔菌;食品级牛黄酸;绿茶粉;食品级壳寡糖;食品级维生素B族等成分组成,具有抗氧化、增加心肌细胞对胰岛素的摄取、防止胰岛β细胞氧化破坏、降低糖尿病并发症的作用;同时具备降血糖、调血脂和抗脂质过氧化作用,还可以调节人体的糖代谢,增强胰岛素的活性。还包括该食品的制造方法。
Description
技术领域
本发明属于医疗卫生科学技术领域,具体涉及一种糖尿病患者专用食品及其制作方法。
背景技术
糖尿病是由遗传因素、免疫功能紊乱、微生物感染及其毒素、自由基毒素、饮食因素等各种致病因子作用于机体导致胰岛功能减退、胰岛素抵抗等而引发的糖、蛋白质、脂肪、水和电解质等一系列代谢紊乱综合征,临床上以高血糖为主要特点,典型病例可出现多尿、多饮、多食、消瘦等表现。
糖尿病在中国是一个很大的病,已有1亿多患者,还有很高的发病率,而且还不能治愈。现在,糖尿病患者大都采用服用降糖药或胰岛素,随着服用时间的延长,有的患者效果越来越差,并发症越来越严重,究其原因,降糖药或胰岛素靶点单一,副作用大;如果配合中药食品,发挥中药靶点多,副作用小的优势,二者结合,能够很好的辅助控制住血糖,避免或减轻并发症,将显著提高糖尿病患者的生活质量。
发明内容
发明目的:糖尿病患者专用的降糖食品,它是由富硒菇粉、肉桂提取物、玉竹提取物 、苦瓜粉、桑叶粉、马齿苋提取物、食品级牛黄酸、绿茶粉、食品级壳寡糖、食品级维生素B族加工而成。
技术方案:
一种糖尿病患者专用食品,其特征在于:该食品由以下重量份数的成分组成:
富硒菇粉12~15份;
肉桂提取物12~15份;
玉竹提取物 5~10份;
苦瓜粉10~20份;
桑叶粉6~9份;
马齿苋提取物15~25份;
桦褐孔菌5~10份;
食品级牛黄酸15~25份
绿茶粉5~10份
食品级壳寡糖2~3份
食品级维生素B族 0.002~0.0010份。
上述技术方案所述的糖尿病患者专用食品,优选地:
所述富硒菇粉的硒含量在50~90ug/kg;
所述肉桂粉中的桂皮醛含量为0.9%~1.2%;
所述玉竹提取物的玉竹多糖为8.5%~9.5%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述苦瓜粉中苦瓜素含量为0.35%~0.55%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述桑叶中的桑叶多糖含量为15mg/g~35mg/g。
上述技术方案所述的糖尿病患者专用食品,优选地:所述桦褐孔菌中的三萜2.0%,多糖30%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述食品级牛磺酸含量为95%~98%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述的绿茶粉的茶多酚为180mg/g~210mg/g。
上述技术方案所述的糖尿病患者专用食品,优选地:所述壳寡糖的含量为90%~95%,脱乙酰度大于90%,分子量1000~1500。
上述技术方案所述的糖尿病患者专用食品,优选地:所述食品级维生素B族的含量为98%~99.5%。
一种所述的糖尿病患者专用食品的制作方法,其特征在于:该方法包括以下步骤:
(1)原料的准备:
富硒菇粉:
将0.03~0.045kg的亚硒酸钠用2kg的水充分溶解后,再加13kg水,配成15kg水溶液,即1喷壶;在香菇出菇旺期,进行喷施,每平方米喷施50g水溶液,间隔1天,第二次喷施相同浓度和相同数量的水溶液,再间隔2天,第三次喷施相同浓度和相同数量的水溶液,喷施3次即可;将采收的香菇晾干,进行粉碎,粉碎至80目,然后进行检测,硒含量达到50 ug/kg~90ug/kg,即可做为原料使用;
马齿苋提取物的制备:
将新鲜的马齿苋自然晾干,粉碎成80目粉末,称取10kg,按照10:1的料液比进行较热搅拌提取,60℃提取2h,过滤,加入质量分数0.8%的活性炭,50℃脱色0.5h,离心过滤,得到马齿苋提取液,浓缩,浓缩液冷冻干燥得到马齿苋提取物粉;
肉桂提取物制备:
将肉桂粉碎后,用30%~ 75%乙醇溶液提取两次,合并提取液,将提取液浓缩至几乎无醇味,加浓缩液4 倍~ 6 倍量的水稀释搅拌均匀,静置,除去沉淀物,得到肉桂粗提液;
将上所得的肉桂粗提液加于大孔吸附树脂柱,先用水或不高于20%的低浓度乙醇洗脱,将水或低浓度乙醇洗脱液弃去不用,除去极性大的杂质,再用30%~ 90%的乙醇溶液洗脱,收集洗脱液,回收乙醇并浓缩,干燥,即得肉桂提取物;
玉竹提取物:
称取玉竹粉末10g,放入容器中,加入适量水,放入微波辐射萃取仪中,在功率0.2kw~0.3kw, 60℃~80℃的条件下,提取2小时,过滤合并提取液,减压浓缩至40mL~80 mL,加入乙醇使醇浓度达到60%~75%,静置24h后过滤,用无水乙醇洗涤沉淀2~3次,每次20~35mL,把沉淀转移到事先称重的蒸发皿中,放入80℃的电热鼓风干燥箱中干燥,即得玉竹提取物;
(2)食品配制:
称取配方量的富硒菇粉、肉桂提取物、玉竹提取物、苦瓜粉、桑叶粉、马齿苋提取物、桦褐孔菌、食品级牛黄酸、绿茶粉、食品级壳寡糖、食品级维生素B族,混拌均匀,用食品袋灌装即可。
优点及效果:本发明具有抗氧化、增加心肌细胞对胰岛素的摄取、防止胰岛β细胞氧化破坏、降低糖尿病并发症的作用;同时具备降血糖、调血脂和抗脂质过氧化作用,还可以调节人体的糖代谢,增强胰岛素的活性。
具体实施方式:
本发明是一种糖尿病患者专用食品,其特征在于:该食品由以下重量份数的成分组成:
富硒菇粉12~15份;
肉桂提取物12~15份;
玉竹提取物 5~10份;
苦瓜粉10~20份;
桑叶粉6~9份;
马齿苋提取物15~25份;
桦褐孔菌5~10份;
食品级牛黄酸15~25份
绿茶粉5~10份
食品级壳寡糖2~3份
食品级维生素B族 0.002~0.0010份。
上述技术方案所述的糖尿病患者专用食品,优选地:
所述富硒菇粉的硒含量在50~90ug/kg;
所述肉桂粉中的桂皮醛含量为0.9%~1.2%;
所述玉竹提取物的玉竹多糖为8.5%~9.5%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述苦瓜粉中苦瓜素含量为0.35%~0.55%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述桑叶中的桑叶多糖含量为15mg/g~35mg/g。
上述技术方案所述的糖尿病患者专用食品,优选地:所述桦褐孔菌中的三萜2.0%,多糖30%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述食品级牛磺酸含量为95%~98%。
上述技术方案所述的糖尿病患者专用食品,优选地:所述的绿茶粉的茶多酚为180mg/g~210mg/g。
上述技术方案所述的糖尿病患者专用食品,优选地:所述壳寡糖的含量为90%~95%,脱乙酰度大于90%,分子量1000~1500。
上述技术方案所述的糖尿病患者专用食品,优选地:所述食品级维生素B族的含量为98%~99.5%。
一种所述的糖尿病患者专用食品的制作方法,其特征在于:该方法包括以下步骤:
(1)原料的准备:
富硒菇粉:
将0.03~0.045kg的亚硒酸钠用2kg的水充分溶解后,再加13kg水,配成15kg水溶液,即1喷壶;在香菇出菇旺期,进行喷施,每平方米喷施50g水溶液,间隔1天,第二次喷施相同浓度和相同数量的水溶液,再间隔2天,第三次喷施相同浓度和相同数量的水溶液,喷施3次即可;将采收的香菇晾干,进行粉碎,粉碎至80目,然后进行检测,硒含量达到50 ug/kg~90ug/kg,即可做为原料使用;
马齿苋提取物的制备:
将新鲜的马齿苋自然晾干,粉碎成80目粉末,称取10kg,按照10:1的料液比进行较热搅拌提取,60℃提取2h,过滤,加入质量分数0.8%的活性炭,50℃脱色0.5h,离心过滤,得到马齿苋提取液,浓缩,浓缩液冷冻干燥得到马齿苋提取物粉;
肉桂提取物制备:
将肉桂粉碎后,用30%~ 75%乙醇溶液提取两次,合并提取液,将提取液浓缩至几乎无醇味,加浓缩液4 倍~ 6 倍量的水稀释搅拌均匀,静置,除去沉淀物,得到肉桂粗提液;
将上所得的肉桂粗提液加于大孔吸附树脂柱,先用水或不高于20%的低浓度乙醇洗脱,将水或低浓度乙醇洗脱液弃去不用,除去极性大的杂质,再用30%~ 90%的乙醇溶液洗脱,收集洗脱液,回收乙醇并浓缩,干燥,即得肉桂提取物;
玉竹提取物:
称取玉竹粉末10g,放入容器中,加入适量水,放入微波辐射萃取仪中,在功率0.2kw~0.3kw, 60℃~80℃的条件下,提取2小时,过滤合并提取液,减压浓缩至40mL~80 mL,加入乙醇使醇浓度达到60%~75%,静置24h后过滤,用无水乙醇洗涤沉淀2~3次,每次20~35mL,把沉淀转移到事先称重的蒸发皿中,放入80℃的电热鼓风干燥箱中干燥,即得玉竹提取物;
(2)食品配制:
称取配方量的富硒菇粉、肉桂提取物、玉竹提取物、苦瓜粉、桑叶粉、马齿苋提取物、桦褐孔菌、食品级牛黄酸、绿茶粉、食品级壳寡糖、食品级维生素B族,混拌均匀,用食品袋灌装即可。
本发明能起到如下技术效果:
1.本专利提供的糖尿病患者专用食品采用富硒菇粉中的硒元素在糖尿病患者体内的作用主要包括一下6个方面:①硒的抗氧化作用。因糖尿病相关的许多并发症都与糖尿病所致体内自由基增多相关,而硒有抗氧化作用,能消除这些自由基。②硒的胰岛素样作用。最近的研究证明硒有胰岛素样作用。当机体在缺硒条件下,糖尿病大鼠心肌细胞胰岛素含量降低,而补硒可明显增加心肌细胞对胰岛素的摄取。③帮助增强免疫力:硒能帮助清除体内自由基,有助于排除体内毒素、抗氧化,帮助抑制过氧化脂质的产生,对延缓衰老乃至预防某些慢性病的发生起到帮助作用;④帮助防治糖尿病:硒是构成谷胱甘肽过氧化物酶的活性成分,它能帮助防止胰岛β细胞氧化破坏,使其功能正常,有助于促进糖份代谢、降低血糖和尿糖,帮助改善糖尿病患者的症状;⑤帮助防止心脑血管疾病:硒是帮助维持心脏正常功能的重要元素,对心脏肌体有帮助保护和修复的作用。补硒对预防心脑血管疾病、高血压、动脉硬化等都有较好的帮助作用。
⑥降低糖尿病并发症
给糖尿病患者补硒,除了有助于控制血糖浓度以外,还有利于降低各种并发症发生,如预防冠状动脉粥样硬化、白内障、高血压、心肌梗死和心绞痛。
2.肉桂提取物能够重新激活脂肪细胞对胰岛素的反应能力,大大加快葡萄糖的新陈代谢;进一步研究表明,桂皮中起作用的成分是甲基羟查尔铜聚合物。肉桂治疗糖尿病的另一个优点是它所含的热卡微乎甚微。食用肉桂还可以帮助那些糖尿病高发人群预防糖尿病的发生。肉桂还可以强化胰岛素的分泌,还具有极强的抗氧化能力,并清除血中坏的胆固醇,有利于降血糖和血脂。
3.玉竹提取物具有降血糖、调血脂和抗脂质过氧化作用,可明显改善糖尿病的糖脂代谢紊乱。对葡萄糖、四氧嘧啶引起的高血糖也有抑制作用。玉竹能非常显著地降低造模后小鼠的血清葡萄糖和甘油三脂水平,升高血清胰岛素水平。玉竹多糖对糖尿病有比较好的而治疗效果。
4.苦瓜中的苦瓜皂甙有非常明显的降血糖作用,不仅有类胰岛素样作用,堪称“植物胰岛素”,而且有刺激胰岛素释放的功能。用苦瓜给Ⅱ型糖尿病病人口服治疗,有比较好的降糖效果。苦瓜粉中含有甾体皂甙如苦瓜素,类胰岛素肽类和生物碱,这些物质赋予苦瓜降血糖活性。苦瓜素刺激胰岛素的释放和阻碍血流中葡萄糖的形成。P-胰岛素(或v-胰岛素,因其为植物胰岛素),其在结构上为大分子多肽构型,而药理学上与牛胰岛素相近,对糖尿病患者有降血糖作用。
5.桑叶中含有脱氧霉素,可阻止糖分解酶发挥作用。桑叶具有抑制血糖上升的功能,其主要功能成份是桑叶中的“生物碱”,这是一种具有特殊功能的成份,它是其它动、植物所没有的。日本医学界称这种特殊组成为“DNJ”物质。其主要作用是抑制蔗糖酶、麦芽糖酶、a-葡萄糖甘糖、a-淀粉酶的分解,能刺激胰岛素分泌,降低胰岛素分解速度。
6.马齿苋含有大量的去甲肾上腺素能促进胰岛腺分泌胰岛素,调节人体内糖代谢。具有降低血糖浓度,保持血糖稳定的作用。对治疗糖尿病有良效。马齿苋对于改善糖尿病的多饮多食症状,稳定血糖,改善胰岛细胞功能有一定的作用。
7.桦褐孔菌可显著增强过氧化氢酶,超氧化物歧化酶(SOD )和谷胱甘肽过氧化酶的活性。这些酶可降低糖尿病小鼠的丙二酸水平,同时修复已损伤的胰腺组织。桦褐孔菌抗病毒作用也为降低胰岛毒性,促进胰岛素分泌起到积极作用。桦褐孔菌中有一种类似人体胰岛素的物质一一真菌多糖肽,有明显的平衡血糖功效,对糖尿病效果很有效。桦褐孔菌可改善糖尿病糖尿病患者肝脏代谢紊乱,增强肝细胞合成肝糖原的功能而发挥降低血糖的作用;桦褐孔菌能明显降低血中糖化血红蛋白水平和血清血脂水平,且有抗氧化作用,其对糖尿病患者早期肾脏病变有明显改善作用;桦褐孔菌中的β 一葡聚糖、杂多糖和蛋白复合物,桦褐孔菌多糖降低血糖的作用可长达48小时;桦褐孔菌中的栓菌酸对非胰岛素依赖症糖尿病有效,桦褐孔菌提取通过增强 cK (葡萄糖激酶、一种葡萄糖分解代谢关键酶)表达,促进葡萄糖分解代谢过程,降低血糖和血红蛋白酶化过程,进而通过降低HMGOOA还原酶的表达而达到防治糖尿病的作用;桦褐孔菌治疗后的全血粘度、血浆粘度、纤维蛋白质、红细胞压积、红细胞聚集指数比治疗前明显降低,有效净化血管,改善脂代谢,防止心脑血管等糖尿病并发症。
8.牛磺酸能促进利用糖,牛磺酸可与胰岛素受体结合,促进细胞摄取和利用葡萄糖,加速糖酵解,降低血糖浓度。牛磺酸具有一定的降血糖作用,且不依赖于增加胰岛素的释放。牛磺酸对细胞糖代谢的调节作用可能是通过受体后机制实现的,它主要依靠与胰岛素受体蛋白的相互作用。牛磺酸能抑制白内障的发生发展,牛磺酸具有调节晶体渗透压和抗氧化等重要作用,在白内障发生发展过程中,晶状体中山梨酸含量增加,晶体渗透压增加,而作为调节渗透压的重要物质牛磺酸浓度则明显降低,抗氧化作用减弱,晶体中的蛋白质发生过度氧化,从而引起或加重白内障的发生。补充牛磺酸可抑制白内障的发生发展。牛磺酸能促进垂体激素分泌,活化胰腺功能。
9.绿茶粉的作用机理主要是通过调控糖代谢平衡:包括降低α-糖苷酶、α-淀粉酶等双糖酶活性,调控胰岛素信号传导途径及AMPK途径中多个分子靶点的磷酸化水平,影响酶与转录因子的活性与表达,减弱胰岛素抵抗及糖异生作用,促进胰岛素的合成与分泌,促进靶组织对葡萄糖的吸收与利用等;同时,茶多酚能够调控脂代谢,通过抑制脂质合成与积累的相关酶的活性及转录因子的表达,促进脂质的氧化代谢,减轻脂代谢紊乱;另外,茶多酚的抗氧化与抗炎作用可以有效减轻组织细胞的氧化伤害和炎症损伤,减少细胞凋亡。
10.壳寡糖对糖尿病主要有以下作用:
①调节人体 pH,增强胰岛素活性:研究表明人体体液 pH 每下降 0.1 个单位,胰岛素的活 性下降 30%。壳寡糖带有碱性基团(-NH2),它在体内可使酸性体液恢复碱性,可使胰岛素活性增强,分泌量和利用率增加,同时又维持体液酸碱平衡,从而缓解糖尿病症 状。
②活化、修复细胞,提高胰岛β细胞的数量及功能:阎春玲等[2]研究表明,低分子水溶 性壳聚糖(500mg/kg、1000mg/kg)能使糖尿病小鼠血糖显著降低,胰岛β细胞明显增多。刘冰、陈列欢等[3]研究发现,壳寡糖对原代培养的胰岛细胞和胰岛β细胞系 NIT- 1 有促增殖的作用。 另外,Lee 等[4]研究显示,给予 STZ 至非胰岛依赖性糖尿病大鼠 0.3%低聚糖后空 腹血糖降低 10%,胰岛素分泌显著增加,这都是胰岛β细胞功能改善和胰岛分泌正常化 的结果。
③刺激迷走神经,促进胰岛素分泌:服用壳寡糖吸收后,刺激肝脏的迷走神经,兴奋大 脑皮层的饥饿中枢和血管运动中枢,最终会引起全身副交感神经而使细小动脉扩展,毛细血管的血流量也随之增加。因循环血流量增加使肌肉细胞的氧气及营养供应量增 加,脂肪无氧,氧化减少,蓄滞在体内的二氧化碳等酸性物质排出量增加。同时,使 胰腺的血管扩展,增加循环血液循环量,胰岛素的分泌也增加。有研究报道称[5],随 着分子量的减小,胰岛素的释放量随之增大,COS 分子量为 1200Da 作用效果尤为显著。
④控制餐后高血糖。
11.维生素B族对糖尿病人的作用:烟酸是葡萄糖耐量因子的组成成分,具有增强胰岛素效力的作用,即使体内烟酸含量正常。一个正常人缺乏维生素B6时会出现血糖升高,补充维生素B6后血糖恢复正常。因此,糖尿病患者适当补充维生素B6将有助于控制血糖。维生素B1对糖尿病患者的血管有很好的保健作用。对糖尿病患者对血管病变,大血管并发症(如心梗、中风、周围血管疾病)和微血管并发症(如肾病、视网膜病变)有很好的改善作用。维生素B1和B6都对于改善糖尿病神经病变症状有作用。维生素B12更是治疗糖尿病神经病变的经典药物。维生素B族对糖尿病肾病 、预防高血压 也有很明显的作用。同时,对于长期服用二甲双胍的糖尿病患者来说更容易出现维生素B12缺乏,因此需要适当补充维生素B12。维生素B6的糖尿病作用,人体缺乏维生素B6,糖尿病患者吸收的色氨酸,就不能被身体正常利用,转化为一种有毒的黄尿酸,黄尿酸在血中过高时,48小时就会使胰脏受损,不分泌胰岛素而发生糖尿病,同时血糖升高,不断从尿中排出,如果一直服用维生素B6,糖尿病就会步步加重,直至死亡。
以实施例对本发明进行说明
实施例1
本实施例由如下配方组成:
按重量份数:
富硒菇粉15份;
肉桂提取物15份;
玉竹提取物 5份;
苦瓜粉10份;
桑叶粉6份;
马齿苋提取物15份;
桦褐孔菌5份;
食品级牛黄酸15份;
绿茶粉5份;
食品级壳寡糖2份;
食品级维生素B族 0.002份。
本配方具有较好的增强免疫力及抗氧化功能。
实施例2
按重量份数
富硒菇粉12份;
肉桂提取物12份;
玉竹提取物 5份;
苦瓜粉10份;
桑叶粉6份;
马齿苋提取物15份;
桦褐孔菌5份;
食品级牛黄酸15份;
绿茶粉10份;
食品级壳寡糖3份;
食品级维生素B族 0.0010份。
该配方具备控制餐后血糖,修复细胞,调控糖代谢平衡,增强过氧化氢酶,超氧化物歧化酶(SOD )和谷胱甘肽过氧化酶的活性等功能。
Claims (10)
1.一种糖尿病患者专用食品,其特征在于:该食品由以下重量份数的成分组成:
富硒菇粉12~15份;
肉桂提取物12~15份;
玉竹提取物 5~10份;
苦瓜粉10~20份;
桑叶粉6~9份;
马齿苋提取物15~25份;
桦褐孔菌5~10份;
食品级牛黄酸15~25份;
绿茶粉5~10份;
食品级壳寡糖2~3份;
食品级维生素B族 0.002~0.0010份。
2.根据权利要求1所述的糖尿病患者专用食品,其特征在于:
所述富硒菇粉的硒含量在50~90ug/kg;
所述肉桂粉中的桂皮醛含量为0.9%~1.2%;
所述玉竹提取物的玉竹多糖为8.5%~9.5%。
3.根据权利要求1所述的糖尿病患者专用食品,其特征在于:所述苦瓜粉中苦瓜素含量为0.35%~0.55%。
4.根据权利要求1所述的糖尿病患者专用食品,其特征在于:所述桑叶中的桑叶多糖含量为15mg/g~35mg/g。
5.根据权利要求1所述的糖尿病患者专用食品,其特征在于:所述桦褐孔菌中的三萜2.0%,多糖30%。
6.根据权利要求1所述的糖尿病患者专用食品,其特征在于:所述食品级牛磺酸含量为95%~98%。
7.根据权利要求1所述的糖尿病患者专用食品,其特征在于:所述的绿茶粉的茶多酚为180 mg/g~210mg/g。
8.根据权利要求1所述的糖尿病患者专用食品,其特征在于:所述壳寡糖的含量为90%~95%,脱乙酰度大于90%,分子量1000~1500。
9.根据权利要求1所述的糖尿病患者专用食品,其特征在于:所述食品级维生素B族的含量为98%~99.5%。
10.一种如权利要求1所述的糖尿病患者专用食品的制作方法,其特征在于:该方法包括以下步骤:
(1)原料的准备:
富硒菇粉:
将0.03~0.045kg的亚硒酸钠用2kg的水充分溶解后,再加13kg水,配成15kg水溶液,即1喷壶;在香菇出菇旺期,进行喷施,每平方米喷施50g水溶液,间隔1天,第二次喷施相同浓度和相同数量的水溶液,再间隔2天,第三次喷施相同浓度和相同数量的水溶液,喷施3次即可;将采收的香菇晾干,进行粉碎,粉碎至80目,然后进行检测,硒含量达到50 ug/kg~90ug/kg,即可做为原料使用;
马齿苋提取物的制备:
将新鲜的马齿苋自然晾干,粉碎成80目粉末,称取10kg,按照10:1的料液比进行较热搅拌提取,60℃提取2h,过滤,加入质量分数0.8%的活性炭,50℃脱色0.5h,离心过滤,得到马齿苋提取液,浓缩,浓缩液冷冻干燥得到马齿苋提取物粉;
肉桂提取物制备:
将肉桂粉碎后,用30%~ 75%乙醇溶液提取两次,合并提取液,将提取液浓缩至几乎无醇味,加浓缩液4 倍~ 6 倍量的水稀释搅拌均匀,静置,除去沉淀物,得到肉桂粗提液;
将上所得的肉桂粗提液加于大孔吸附树脂柱,先用水或不高于20%的低浓度乙醇洗脱,将水或低浓度乙醇洗脱液弃去不用,除去极性大的杂质,再用30%~ 90%的乙醇溶液洗脱,收集洗脱液,回收乙醇并浓缩,干燥,即得肉桂提取物;
玉竹提取物:
称取玉竹粉末10g,放入容器中,加入适量水,放入微波辐射萃取仪中,在功率0.2kw~0.3kw, 60℃~80℃的条件下,提取2小时,过滤合并提取液,减压浓缩至40mL~80 mL,加入乙醇使醇浓度达到60%~75%,静置24h后过滤,用无水乙醇洗涤沉淀2~3次,每次20~35mL,把沉淀转移到事先称重的蒸发皿中,放入80℃的电热鼓风干燥箱中干燥,即得玉竹提取物;
(2)食品配制:
称取配方量的富硒菇粉、肉桂提取物、玉竹提取物、苦瓜粉、桑叶粉、马齿苋提取物、桦褐孔菌、食品级牛黄酸、绿茶粉、食品级壳寡糖、食品级维生素B族,混拌均匀,用食品袋灌装即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710812310.7A CN107468898A (zh) | 2017-09-11 | 2017-09-11 | 一种糖尿病患者专用食品及其制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710812310.7A CN107468898A (zh) | 2017-09-11 | 2017-09-11 | 一种糖尿病患者专用食品及其制作方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107468898A true CN107468898A (zh) | 2017-12-15 |
Family
ID=60584934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710812310.7A Pending CN107468898A (zh) | 2017-09-11 | 2017-09-11 | 一种糖尿病患者专用食品及其制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107468898A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112205617A (zh) * | 2019-07-11 | 2021-01-12 | 天赋能健康产业集团股份有限公司 | 一种适宜糖尿病及需要控制血糖人群食用的膳食 |
CN112438397A (zh) * | 2020-12-11 | 2021-03-05 | 安徽国膳生物科技有限公司 | 一种供高血糖人群食用的药膳 |
CN112826926A (zh) * | 2021-03-12 | 2021-05-25 | 浙江丽申医疗健康科技有限公司 | 一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 |
CN113519852A (zh) * | 2021-07-27 | 2021-10-22 | 赣州照桥苑健康咨询有限公司 | 一种富硒壳寡糖片及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101474213A (zh) * | 2007-12-31 | 2009-07-08 | 郭宏旗 | 防治心脑血管疾病的保健品及其制备方法 |
CN102652801A (zh) * | 2011-03-03 | 2012-09-05 | 陕西诺华生物工程有限公司 | 一种降血糖及防治糖尿病并发症的中草药袋泡茶 |
CN102727586A (zh) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | 预防和治疗糖尿病的组合物 |
CN102726648A (zh) * | 2012-05-28 | 2012-10-17 | 北京康比特体育科技股份有限公司 | 一种低血糖指数的提神醒脑的组合物 |
CN103156108A (zh) * | 2013-04-02 | 2013-06-19 | 曾晓飞 | 一种防治糖尿病高血压病症的强化食品 |
CN104663243A (zh) * | 2015-01-29 | 2015-06-03 | 谢光玉 | 一种富硒香菇的栽培方法 |
CN105595308A (zh) * | 2015-11-27 | 2016-05-25 | 青岛银色世纪健康产业集团有限公司 | 一种具有辅助降血糖功能的壳寡糖复合粉及其制备方法 |
CN105907819A (zh) * | 2016-06-22 | 2016-08-31 | 潍坊华诺生物科技有限公司 | 一种可控窄分子量功能性壳寡糖的生物酶解生产方法 |
-
2017
- 2017-09-11 CN CN201710812310.7A patent/CN107468898A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101474213A (zh) * | 2007-12-31 | 2009-07-08 | 郭宏旗 | 防治心脑血管疾病的保健品及其制备方法 |
CN102652801A (zh) * | 2011-03-03 | 2012-09-05 | 陕西诺华生物工程有限公司 | 一种降血糖及防治糖尿病并发症的中草药袋泡茶 |
CN102727586A (zh) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | 预防和治疗糖尿病的组合物 |
CN102726648A (zh) * | 2012-05-28 | 2012-10-17 | 北京康比特体育科技股份有限公司 | 一种低血糖指数的提神醒脑的组合物 |
CN103156108A (zh) * | 2013-04-02 | 2013-06-19 | 曾晓飞 | 一种防治糖尿病高血压病症的强化食品 |
CN104663243A (zh) * | 2015-01-29 | 2015-06-03 | 谢光玉 | 一种富硒香菇的栽培方法 |
CN105595308A (zh) * | 2015-11-27 | 2016-05-25 | 青岛银色世纪健康产业集团有限公司 | 一种具有辅助降血糖功能的壳寡糖复合粉及其制备方法 |
CN105907819A (zh) * | 2016-06-22 | 2016-08-31 | 潍坊华诺生物科技有限公司 | 一种可控窄分子量功能性壳寡糖的生物酶解生产方法 |
Non-Patent Citations (1)
Title |
---|
《中国营养产品与品牌》年鉴编委会: "《中国营养产品与品牌年鉴:2005~2006版》", 31 May 2007, 新华出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112205617A (zh) * | 2019-07-11 | 2021-01-12 | 天赋能健康产业集团股份有限公司 | 一种适宜糖尿病及需要控制血糖人群食用的膳食 |
CN112438397A (zh) * | 2020-12-11 | 2021-03-05 | 安徽国膳生物科技有限公司 | 一种供高血糖人群食用的药膳 |
CN112826926A (zh) * | 2021-03-12 | 2021-05-25 | 浙江丽申医疗健康科技有限公司 | 一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 |
CN113519852A (zh) * | 2021-07-27 | 2021-10-22 | 赣州照桥苑健康咨询有限公司 | 一种富硒壳寡糖片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107468898A (zh) | 一种糖尿病患者专用食品及其制作方法 | |
CN107080250A (zh) | 一种辅助降血糖的组合物、饮料及其制备方法 | |
KR101756804B1 (ko) | 참당귀 잎 추출물을 포함하는 항염 및 항당뇨 기능성 조성물 및 한방소스 제조방법 | |
CN111919934A (zh) | 一种用于降三高保护心血管的红花苏心茶及其制备方法 | |
WO2021078288A1 (zh) | 活化胰岛素及治疗糖尿病的复合苦瓜肽口服药及制备方法 | |
KR101261029B1 (ko) | 칠면초를 포함하는 당뇨병 예방 또는 개선용 조성물 | |
CN103168882A (zh) | 一种有益降血糖和减缓糖尿病并发症的保健茶 | |
KR20150085566A (ko) | 항고혈압 저염 간장의 제조방법 | |
CN108815230A (zh) | 用于治疗糖尿病的中药组合物及其制备方法和应用 | |
KR102298044B1 (ko) | 결명자 추출물을 포함하는 당뇨병 예방 또는 치료용 조성물 | |
KR101995281B1 (ko) | 곰취 추출물 및 여주 추출물을 포함하는 예방 및 치료용 조성물 및 이의 제조 방법 | |
KR20210052731A (ko) | 블랙베리 추출물을 포함하는 지방간, 당뇨병 또는 비만의 예방 또는 개선용 조성물 | |
CN110327383A (zh) | 一种含桦树茸降血糖片剂及其制备方法 | |
KR100697184B1 (ko) | 인삼과 상엽과 바나바엽을 주재로 한 혈당강하용 기능성 식품 및 그 제조방법 | |
CA2821861C (en) | Composition comprising cinnamon extract | |
CN113796537B (zh) | 一种降糖组合物及其制作工艺 | |
JP4043645B2 (ja) | ヤーコン・桑葉配合食品 | |
KR101808808B1 (ko) | 벌나무 및 후박나무 추출물을 함유하는 당뇨병 또는 당뇨합병증 예방 및 치료용 조성물 | |
CN107183718A (zh) | 一种糖尿病患者专用食品及其制作方法 | |
KR102624358B1 (ko) | 돌콩 발효물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물 | |
CN110801469A (zh) | 一种调节血糖的功能性食品及其制备方法 | |
KR102438182B1 (ko) | 오디를 포함하는 발아현미 제조용 배지 조성물을 이용한 발아현미 조성물의 제조방법 | |
KR102438190B1 (ko) | 오미자를 함유하는 발아현미 조성물의 제조방법 | |
JP2014043432A (ja) | 桑小枝、桑葉及びオオマツヨイグサをイオン化デキストリンで造粒して顆粒状または成形した錠剤等の製造方法と生理活性 | |
KR102158337B1 (ko) | 음나무 식초를 유효성분으로 함유하는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171215 |
|
RJ01 | Rejection of invention patent application after publication |